Nadim Ahmed, Cullinan Oncology CEO
May 12, 2022 02:52 AM EDTUpdated 07:06 AM
Deals

Cul­li­nan On­col­o­gy goes full cir­cle, scor­ing $275M for shar­ing the load on EGFR in­hibitor with orig­i­nal de­vel­op­er

Paul Schloesser

Associate Editor

On­ly a few months af­ter CEO Nadim Ahmed came over from Bris­tol My­ers Squibb and joined as the top brass at the can­cer-fo­cused biotech Cul­li­nan …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times